In a Facebook Live interview from Cape Town, South Africa earlier this week, we heard from NIH’s Dr. Carl Dieffenbach about the exciting launch of HVTN 702, a new HIV Vaccine Clinical Trial supported by NIH. The first HIV vaccine efficacy study to launch anywhere in seven years, HVTN 702 is testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults.
Read more about the HVTN 702 trial.
This post first appeared on Blog.aids.gov — HIV Policy & Programs. Research. New Media., please read the originial post: here
